Tuesday, 15 Oct 2019

You are here

Quarterly Canakinumab Reduces Gout Risk Without Affecting Uric Acid

The Annals of Internal Medicine reports that interleukin-1 (IL-1) inhibitor treatment is associated with a reduced risk of gout attacks - such are the findings of an anlysis of the CANTOS study previously reported at the Annual ACR 2017 meeting in Washington, DC. 

The CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study) study set out to assess whether antiinflammatory therapy, in the form of an IL-1 inhibitor canakinumab, could reduce risk of a future cardiovascular event in high risk individuals.  The results were reported in 2017 in the Lancet and NEJM and showed that canakinumab, 150 mg every 3 months significantly lowered rate of recurrent cardiovascular events (independent of lipid-level lowering) and it also reduced total cancer deaths, especially lung cancer. These effects were dose dependent.

Solomon et al. now reports on the effects on quarterly canakinumab on serum uric acid (sUA) levels and gout attacks in the 10,059 patients enrolled with a history of prior myocardial infarction and an elevated high-sensitivity C-reactive protein (hsCRP) level. Patients were followed for a median of 3.7 years.

Among placebo treated patients, the frequency of gout rose nearly 20 fold as sUA concentrations rose from 404.6 to 535.4 µmol/L or higher (gout risk rose from 0.28 to 5.94, respectively, per 100 person-years).

Receiving canakinumab was not associated with reductions in sUA over time but was associated with significantly reduced rates of gout attacks (hazard ratios ranged from 0.40 to 0.48).  Thus IL-1 inhibition lead to a 50-60% reduction in gout attacks along with a significant drop in CRP levels, but no effect on sUA levels. 

 While these data and other studies showing the efficacy of IL-1 inhibition in treating acute gout are encouraging, the cost of biologic therapy to either treat or prevent gout makes such therapies impractical for most.  Nonetheless, there may be benefits to targeting IL-1 and innate immunity in those at risk for gout.

Editors note: canakinumab is not FDA approved for use in gout. It is FDA approved for use in systemic JIA and Periodic Fever syndromes (CAPS, FMF, HIDS).

Disclosures: 
The author has received research/grant financial support on this subject

Rheumatologists' Comments

Barring the notable cost, I have contemplated a dose of Canakinumab prior to beginning Krystexxa (how to obtain it would be another issue), given the frequent flares associated with treatment. The 3 month benefit of a single dose may be all that is required?
The only proper start to this is to say you cannot take cost off the table - the annual cost of ILARIS is over $100,000. The list price of one injection is $16,769. I would love to take a rocket ship to work in 0.6 nanoseconds, but at a cost of $10,000 per trip Im afraid my wife would kill me, even if I could afford it. The reason I reported this was to encourage research and thinking about treating the innate immune response in Gout control. This research is a start....in my opinion. Thanks for mind bending conversations thats how we get to great for our patients! JC

More Like This

Anakinra Use in Hospitalized Gout Patients

While the efficacy and safety of interleukin 1 (IL-1) inhibitors (e.g., anakinra) in the acute management of gout and pseudogout has been repeatedly shown, the cost efficacy of such biologic therapy has rendered it impractical for most. A new retrospective study has shown that IL-1 inhibitors may be effective and appropriate for some medically complex, hospitalized patients with acute gout or calcium pyrophosphate crystal arthritis.

Higher Rates of Venous Thromboembolism in Gout

A Canadian administrative claims analysis has shown that gout-associated inflammation increases the risk of venous thromboembolism (VTE), deep vein thrombosis (DVT), and pulmonary embolism (PE) before and after the diagnosis of gout.

Modifiable Risk Factors for Hyperuricemia

Choi and colleagues have shown that four modifiable risk factors (BMI, the DASH diet, alcohol use, and diuretic use) could individually account for a notable proportion of observed hyperuricemia. 

Researchers examine modifiable risk factors for hyperuricemia and how this could be prevented through risk factor modification in the general population.

Opioids Overused in Acute Gout

Opioids were commonly given to patients as a treatment for acute gout attacks, despite the availability of other effective and appropriate therapies, a retrospective study found.

Allopurinol Fails to Curtail Hypertension

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. A novel trial presented at EULAR 2019 last week assessed whether the use of urate-lowering therapy (ULT) would control hypertension in those at risk; however, results of this trial were largely negative.

Hypertension is one of the many comorbidities that plagues gout patients.